Chlorhexidine with nystatin
Brand names: Nystaform
A topical/cutaneous preparation combining chlorhexidine, a cationic biguanide antiseptic, with nystatin, a polyene antifungal, used to treat or prevent superficial bacterial and candidal skin infection, particularly in moist or macerated flexural areas.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Chlorhexidine disrupts bacterial cell membranes and is bactericidal against a broad range of organisms, while nystatin binds ergosterol in the fungal cell membrane, increasing permeability and killing Candida species.
Prescribing in practice
- Nystatin is not absorbed through intact skin and chlorhexidine has negligible systemic absorption, so the principal risk is local irritation or contact sensitisation rather than systemic toxicity.
- Keep chlorhexidine away from the eyes, middle ear and meninges, as it can cause irritation of these tissues.
- Reserve for confirmed or strongly suspected mixed bacterial and candidal infection rather than routine use, to limit sensitisation and resistance.
Monitoring
No laboratory monitoring is required; review the treated area clinically and stop if irritation, worsening or no improvement occurs.
Counselling the patient
- Apply a thin layer to the affected area as directed and keep the skin clean and as dry as possible.
- Stop and seek advice if the skin becomes more red, itchy or sore, which may indicate a reaction.
Evidence & guidelines
Topical antiseptic-antifungal combinations are long-established for superficial mixed skin infection; choice should follow local guidance and infection-control principles.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD